Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. - Wikidata - wikimedia - TriplyDB

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

http://www.wikidata.org/entity/Q36654926

about

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Stem cell transplantation in chronic lymphocytic leukemia Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Clinical implications of the molecular genetics of chronic lymphocytic leukemia Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation.The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Alemtuzumab for B-cell chronic lymphocytic leukemia.The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.Management of chronic lymphocytic leukemia.Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellu NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.How I treat CLL up front.Predicting survival in chronic lymphocytic leukemia.Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review The European LeukemiaNet: achievements and perspectives.Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)The spectrum of use of rituximab in chronic lymphocytic leukemia Allogeneic hematopoietic cell transplantation in the treatment of chronic lymphocytic leukemia: why and when?Allogeneic transplantation for chronic lymphocytic leukemia Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Chronic lymphocytic leukemia: treatment options for patients with refractory disease.Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.Hematopoietic stem cells: transcriptional regulation, ex vivo expansion and clinical application.State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.Allogeneic hematopoietic cell transplant with fludarabine-based reduced-intensity conditioning as treatment for advanced chronic lymphocytic leukemia.Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.Hematopoietic stem cell transplantation for chronic lymphocytic leukemia.Chronic lymphocytic leukemia: inception to cure: are we there?Treatment options for high-risk chronic lymphocytic leukaemia.Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist

P2860

Q24616084-20C4E411-1988-45E5-8080-BA8F842BA6B9 Q24642921-F6FDF292-E35D-4F6C-AFDB-A67B237AE196 Q26768154-B88136EB-FCA1-4493-B211-7C788A14AB11 Q26830955-6012F048-31ED-4CAC-93B1-1E85741F7430 Q27021206-602A719C-CD36-4CC1-AE77-AA50616942B1 Q27851685-F46D16FC-FC23-45E1-B9A3-13E7A58BFF99 Q28082120-721B6EED-873B-4283-9F67-9C149AF2B8F6 Q28388806-4D29DEAE-8A75-407D-8C14-E4E9BFD34F91 Q30238945-B9A4D602-2F56-4D0B-93DF-38B6B74DC31B Q30243968-DC90DF2E-F66E-413F-AD87-D8B656DD376B Q33380135-54505B59-0C48-4061-83CE-DF40A0440ADB Q33406164-83FF1082-EA74-49F3-BDF7-54CD3ECA940B Q33417548-94A9C10E-AB33-4001-BFCB-F95E73E698AE Q33558148-D782BE43-8E85-4E3D-B258-7C3B53B32450 Q33595764-461B3DB0-C6C0-4575-B8E1-B567A40EB11B Q33695912-2999DBD6-AD52-4B3B-A45E-5DDBAEAB28BD Q33779931-0019C65A-7E45-4BD9-B354-2309CCB50882 Q33886185-EC1D8F67-8E54-4815-A42D-47998B6FD459 Q34044024-570188C8-94AC-41DA-98E1-B94B9E792C6D Q34056568-926C3DB8-DC95-48DA-9D2D-7D5D93B7C86D Q34137158-2DE26368-18D6-4879-B64F-EBD5FBDCEBE0 Q34257190-5AB7867B-AD01-4FA8-86AD-15FEFA4C1F8A Q34348572-FD3B2FEC-25FD-4C81-AAE2-B334EF4AF0D4 Q34451619-B34C0642-A827-4A9F-AE9A-18E448473399 Q34508322-48949A7C-0220-4525-8990-56E8D3CD1D5A Q34510030-F88D8786-F0C1-480E-BDEE-25F215BAC4D4 Q34549285-0E3D8FF1-E4B7-413E-A6E7-E9BE978FCEE9 Q34549313-68C5DA2A-ACE4-4C42-BA80-12C41D0F750A Q34625543-7D6BD4FE-18FF-46B2-B4A6-CC6A29C5EF28 Q34769213-03B325D6-55A4-49BF-BBA3-11A2A270A5B9 Q35382716-A38D4B05-DC41-4B64-BABC-1612801F3DA3 Q35679601-0A23DCCD-3667-4A7C-B18D-8F10A1E7D7E3 Q35777496-B2AC1CB0-C8B9-4174-B6BA-9769C1FB0448 Q35860550-6D5664FA-EE45-4E2E-BA0A-074B193291C6 Q36222747-5DFE8AA5-9425-4FFE-B651-715A13E1CA3C Q36223667-ABC1AE0D-D122-407E-AF42-607D9A9EB0D4 Q36416452-EE3570CD-84F2-4CE9-91AF-3C8C9B22B1B5 Q36609259-A64EF338-D3E2-4B80-B6EC-360E9EBB0FFC Q36612587-594063DC-BE1E-4205-850A-641C39D1DE35 Q36884399-CBCD8A2C-4369-46BF-82B2-0051317A9662

P2860

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

http://www.wikidata.org/entity/Q36654926

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Indications for allogeneic ste ...... the EBMT transplant consensus.

@ast

Indications for allogeneic ste ...... the EBMT transplant consensus.

@en

type

label

Indications for allogeneic ste ...... the EBMT transplant consensus.

@ast

Indications for allogeneic ste ...... the EBMT transplant consensus.

@en

prefLabel

Indications for allogeneic ste ...... the EBMT transplant consensus.

@ast

Indications for allogeneic ste ...... the EBMT transplant consensus.

@en

P1433

Q36654926-AD8F7D38-086B-4746-9A3E-37BD35800CF9

P1476

Q36654926-3497F496-5FCA-4040-8CF0-A7BAF9AAE8CF

P2093

Q36654926-2F9A25FE-11B5-4373-A0FF-88E8FD801697

Q36654926-46810E73-20B8-4058-BD94-D49F69F3F139

Q36654926-4DAA2D14-DDE5-4E38-AE5C-B54EF895C41B

Q36654926-7FFF53DE-4FF6-43D7-8511-724B5F5A0E2F

Q36654926-8C235DE4-4DAF-4D13-84DD-648C7AD4B509

Q36654926-AB2C89FF-1236-43A2-812F-4EA93F9C932E

Q36654926-BB594EA3-CB94-4820-B6C5-5E1C76556B21

Q36654926-BF42E324-1F28-42DD-8F37-C649FA56A1A0

Q36654926-E5D69A70-E99E-4943-8CA8-BD291FA62500

Q36654926-E5FF3B19-A2E6-47C9-8D88-8D78318964BE

P2860

Q36654926-01CD74DD-B9F3-4C8B-A0FE-9DE0586CE1E3

Q36654926-0FC6D739-6483-4CFF-9541-B6B0695B6CA5

Q36654926-0FC6F104-55CD-45B3-A8B7-C9FADBC2ABA1

Q36654926-18DD6179-87EA-4A14-849F-C31A1488A8D8

Q36654926-1B44DCCD-D137-4FF3-9B74-3133905F13BC

Q36654926-29BFE6E1-7E8B-4481-9831-E717A959C274

Q36654926-3306A3D8-8F20-4701-B651-DDF6FD22B49B

Q36654926-35AF3F84-8EA2-4F50-B848-0782E739BB4F

Q36654926-372DCDF7-83E1-4A98-B41A-695EAA18E6C9

Q36654926-5B5F9E48-E294-40D0-AF53-69DB5D712ABB

P2888

Q36654926-43B6634C-B6F8-46C6-AA89-B0785F0BCC8E

P304

Q36654926-C948A248-71DB-4406-8DD3-6A25A83B08E2

P31

Q36654926-F59F1289-06C8-47B4-8808-172D17ABF711

P356

Q36654926-EC646D1A-5024-45D4-A522-F4A087411BDD

P433

Q36654926-55CFDE58-F938-42EB-A84B-FBA4C933A1F8

P478

Q36654926-B6A146CE-EB69-42FD-825F-0B1E0646BE50

P50

Q36654926-DA2C2225-A87A-43AA-88CA-ED8425DC8625

P577

Q36654926-F2643A5B-8F87-40DF-8A27-67ACAA1AC51C

P5875

Q36654926-3012AC50-1A21-4E72-BED3-0CDBC65D7FAB

P698

Q36654926-0E361BE0-FFFC-477B-9B50-C1AC68C2EBE4

P921

Q36654926-8BAF5303-DCC2-48EC-B3AE-417817C55564

Q36654926-BDC47D53-11FF-4F20-A640-64A2617AEE4C

P356

P1433

P1476

Indications for allogeneic ste ...... the EBMT transplant consensus

@en

P2093

Chronic Leukemia Working Party of the EBMT

http://www.w3.org/2001/XMLSchema#string

D Milligan

http://www.w3.org/2001/XMLSchema#string

D Niederwieser

http://www.w3.org/2001/XMLSchema#string

E Kimby

http://www.w3.org/2001/XMLSchema#string

E Montserrat

http://www.w3.org/2001/XMLSchema#string

J Schetelig

http://www.w3.org/2001/XMLSchema#string

M Hallek

http://www.w3.org/2001/XMLSchema#string

M Michallet

http://www.w3.org/2001/XMLSchema#string

P Dreger

http://www.w3.org/2001/XMLSchema#string

W Wiktor-Jedrzejczak

http://www.w3.org/2001/XMLSchema#string

P2860

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Genomic aberrations and survival in chronic lymphocytic leukemia

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

How I treat refractory CLL.

P2888

P304

12-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2404441

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Corradini

P577

2006-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6688844

http://www.w3.org/2001/XMLSchema#string

P698

17109028

http://www.w3.org/2001/XMLSchema#string

P921